Invest or not to invest ... Not always an easy question to answer
| Autor: | Avi Kulkarni, Susan Evans, Emery Stephans, Aaron Geist, Quintin Lai |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Strategist
Diagnostic information business.industry Emerging technologies Biochemistry (medical) Clinical Biochemistry Health Care Sector Nanotechnology Data science Unmet needs Intervention (law) Molecular Diagnostic Techniques Cost Savings Informatics Medicine Humans Disease prevention business Automated immunoassay Sequence Analysis Biomarkers Diagnostic Techniques and Procedures |
| Zdroj: | Clinical chemistry. 57(8) |
| ISSN: | 1530-8561 |
| Popis: | Innovation fuels the in vitro diagnostics (IVD)6 industry. The introduction of new technologies has greatly changed the face of the clinical laboratory, and they will continue to impact the industry and the laboratory in the years ahead. Some advances have been evolutionary, building on established core technologies, whereas other advances have been game changers. For diagnostics industry research, business development, and product-development professionals, the question of what technologies will become the products of the future—and which ones will not—is a critical one. The search for the answer starts with a clear understanding of the customer and the clinical need, but the real question is more often not the needs of today but the true unmet needs of the clinical laboratory in the years ahead. What problems do laboratories work through today because no obvious technology solution exists? What new diagnostic information would improve the accuracy or speed of diagnosis? What new biomarker will provide a look to the future and facilitate clinical intervention and disease prevention? Let's take a trip back in time before the PCR, or even further back, before automated immunoassay systems. Innovation was planting the seeds for these important advances. Scientists and technologists were developing technologies to reach lower levels of clinical detection. Computer scientists and engineers were exploring how to tame the power of the microchip, fluidics, miniaturization, solid-state substrates, and informatics to build integrated clinical systems. While these changes were occurring, molecular biologists were exploring how to use the replication capability of DNA to create a new diagnostic field that has produced major advances in infectious disease testing, cancer diagnostics, and the detection and characterization of anomalies in our genetic code that are associated with disease. If you are an industry strategist, business-development manager, or investor, what technologies and breakthroughs occurring today would you … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|